Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 263

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 6
Chunk 263
---
 expensed as incurred. Our research and development expenses include:

•	external costs, including expenses incurred under arrangements with third parties, such as contract research organizations (CROs), contract manufacturing organizations (CMOs), consultants and our scientific advisors; and

•	internal costs, including:

•	employee-related expenses, including salaries, benefits, and stock-based compensation for those individuals involved in research and development efforts;

•	the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and

•	facilities and depreciation, which include direct and allocated expenses for rent of facilities and depreciation.

115

The following table summarizes our research and development expenses incurred for the following periods (in thousands):

    Year Ended December 31,

    2024

    2023

    Naporafenib

    $
    51,248

    $
    31,564

    Other clinical programs

    7,047

    44,892

    Other discovery and preclinical programs

    57,064

    27,365

    Total research and development expenses

    $
    115,359

    $
    103,821

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to conduct our ongoing research and development activities, conduct clinical trials and advance our preclinical research programs toward clinical development, particularly as more of our product candidates move into later stages of development, which typically cost more. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time-consuming. We may never succeed in achieving marketing approval for any of our product candidates.

The timelines and costs with research and development activities are uncertain, can vary significantly for each product candidate and program and are difficult to predict. We anticipate we will make determinations as to which product candidates and programs to pursue and how much funding to direct to each product candidate and program on an ongoing basis in response to preclinical and clinical results, regulatory developments, ongoing assessments as to each product candidate’s and program’s commercial potential, and our ability to enter into collaborations, licenses or other similar agreements to the extent we determine the resources or expertise of a third-party would be beneficial for a given product candidate or program. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates and programs may be subject to future collaborations, licenses, or other agreements, when such arrangements will be secured, if at all, and to what degree such arrangements would affect